Nuclear Medicine Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034

The global nuclear medicine market is experiencing strong expansion driven by increasing adoption of radiopharmaceuticals for both diagnostic imaging and targeted therapy. In 2025, the market was valued at USD 11.77 billion. In 2026, it is projected to grow to USD 13.72 billion, reflecting rising clinical adoption and improved isotope availability. By 2034, the market is expected to reach USD 55.75 billion, growing at a CAGR of 19.15% during 2026-2034.

North America dominated the market in 2025 with a 52.67% share, supported by advanced imaging infrastructure, strong radiopharmaceutical manufacturing capacity, and high usage of PET and SPECT procedures.

Market Overview and Scope

Nuclear medicine involves the use of radiopharmaceuticals for diagnosing and treating diseases such as cancer, cardiovascular disorders, and neurological conditions. It includes PET and SPECT imaging for diagnostics and targeted radionuclide therapy for treatment.

The market is expanding due to rising prevalence of chronic diseases, increasing demand for early and precise diagnosis, and growing adoption of theranostics. Advancements in radioisotope production, imaging systems, and AI-supported diagnostics are further enhancing clinical efficiency and treatment outcomes.

Market Drivers

A key driver of the nuclear medicine market is the increasing use of radiopharmaceuticals in targeted therapy. These therapies allow radiation to directly target diseased cells while minimizing damage to healthy tissues, improving treatment precision and patient outcomes.

Growing approvals of radioligand therapies and expanding clinical applications in oncology are significantly boosting demand. Investments by companies in isotope production, manufacturing facilities, and global distribution networks are also improving product availability.

Market Restraints

High costs of radiopharmaceuticals and inadequate reimbursement policies remain major barriers to market growth. The production, handling, and delivery of nuclear medicine products require specialized infrastructure and strict safety protocols, increasing overall treatment costs.

Limited reimbursement coverage reduces hospital adoption and restricts patient access to advanced diagnostic and therapeutic procedures, particularly in emerging markets.

Market Opportunities

The integration of artificial intelligence into radiopharmaceutical development and imaging workflows is creating strong growth opportunities. AI helps improve target identification, optimize treatment planning, and enhance diagnostic accuracy.

Expansion of theranostics, which combines diagnosis and therapy, is also opening new clinical applications, especially in oncology. Emerging markets offer further opportunities due to rising healthcare investments and increasing disease burden.

Market Segmentation Analysis

By type, diagnostics dominated the market in 2025 due to widespread use of PET and SPECT imaging for disease detection, staging, and monitoring. Therapeutics is expected to grow at a CAGR of 25.74%, driven by increasing use of radioligand therapies and targeted alpha treatments.

By application, oncology accounted for the largest share in 2025 as nuclear medicine plays a critical role in cancer detection and treatment planning. Neurology is expected to grow at a CAGR of 18.70% due to increasing applications in brain disorder diagnosis.

By end user, hospitals and clinics dominated the market in 2025 due to high patient volumes and availability of advanced imaging infrastructure. Diagnostic centers are also expanding rapidly as outpatient imaging demand increases.

Regional Insights

North America led the global market in 2025 with USD 6.20 billion, maintaining its dominance due to strong clinical adoption and advanced radiopharmaceutical infrastructure. The U.S. market is projected at USD 6.81 billion in 2026.

Europe is expected to reach USD 2.21 billion in 2026, driven by strong research activity and expanding theranostic applications. Asia Pacific is projected at USD 2.23 billion in 2026, supported by healthcare infrastructure expansion in China, Japan, and India.

Latin America is expected to reach USD 0.69 billion in 2026, while the Middle East & Africa region, including GCC countries, is projected at USD 0.31 billion.

Competitive Landscape

The nuclear medicine market is semi-fragmented with key players including Novartis AG, Lantheus Holdings, Curium, Bracco, Siemens Healthineers, Bayer AG, and GE HealthCare. These companies are focusing on radiopharmaceutical expansion, acquisitions, and manufacturing capacity enhancement.

Strategic moves such as SHINE's acquisition of Lantheus' SPECT business and Novartis expanding radioligand manufacturing facilities highlight strong industry consolidation and growth momentum.

Conclusion

The global nuclear medicine market is projected to grow from USD 11.77 billion in 2025 to USD 13.72 billion in 2026 and reach USD 55.75 billion by 2034. Strong demand for precision diagnostics, increasing adoption of radiopharmaceutical therapies, and technological advancements in imaging and theranostics will continue to drive long-term market growth.

Segmentation By Type, Application, End User, and Region

By Type * Diagnostics

PET Radiopharmaceuticals

FDG-PET/18F
68Ga
68Cu
11C
Others
- SPECT Radiopharmaceuticals
Technetium-99m
Iodine-123
Xenon-133
Thallium-201
Others
Therapeutics
- Ra-223
- Sm-153
- Lu-177
- I-131
- Y-90
- Others

By Application * Neurology

Cardiology
Oncology
Others

By End-user * Hospitals & Clinics

Diagnostic Centers
Others

By Region * North America (By Type, Application, End User, and Country)

U.S.
Canada

Europe (By Type, Application, End User, and Country/Sub-region)
- Germany
- U.K.
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
Asia Pacific (By Type, Application, End User, and Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
Latin America (By Type, Application, End User, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa (By Type, Application, End User, and Country/Sub-region)
- GCC
- South Africa
- Rest of the Middle East & Africa

Product Code: FBI101812

Table of Content

1. Introduction

1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends

4. Key Insights

4.1. Installed Base of PET/PET CT Scanners (Estimated), By Key Countries, 2025
4.2. Installed Base of Gamma Cameras (Estimated), By Key Countries, 2025
4.3. PET/PET CT Procedure Volume (Estimated), By Key Countries, 2025
4.4. Pipeline Analysis, By Key Players
4.5. Overview: Ga-68 Demand
4.6. Overview: Radioisotope Generators, Current & Future Trends
4.7. Key Industry Developments (Mergers, Acquisitions, New Product Launches, etc.)
4.8. Impact of COVID-19 on the Market
4.9. Regulatory Overview: Key Countries/ Region
4.10. Brief Profiles of Key Manufacturers, Cyclotrons
4.11. Supply Chain Analysis: Radioisotopes

5. Global Nuclear Medicine Market Analysis, Insights and Forecast, 2021-2034

5.1. Market Analysis, Insights and Forecast - By Type
- 5.1.1. Diagnostics
  - 5.1.1.1. PET Radiopharmaceuticals
    - 5.1.1.1.1. FDG-PET/18F
    - 5.1.1.1.2. 68Ga
    - 5.1.1.1.3. 68Cu
    - 5.1.1.1.4. 11C
    - 5.1.1.1.5. Others
  - 5.1.1.2. SPECT Radiopharmaceuticals
    - 5.1.1.2.1. Technetium-99m
    - 5.1.1.2.2. Iodine-123
    - 5.1.1.2.3. Xenon-133
    - 5.1.1.2.4. Thallium-201
    - 5.1.1.2.5. Others
- 5.1.2. Therapeutics
  - 5.1.2.1. Ra-223
  - 5.1.2.2. Sm-153
  - 5.1.2.3. Lu-177
  - 5.1.2.4. I-131
  - 5.1.2.5. Y-90
  - 5.1.2.6. Others
5.2. Market Analysis, Insights and Forecast - By Application
- 5.2.1. Neurology
- 5.2.2. Cardiology
- 5.2.3. Oncology
- 5.2.4. Others
5.3. Market Analysis, Insights and Forecast - By End-user
- 5.3.1. Hospitals & Clinics
- 5.3.2. Diagnostic Centers
- 5.3.3. Others
5.4. Market Analysis, Insights and Forecast - Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America
- 5.4.5. Middle East & Africa

6. North America Nuclear Medicine Market Analysis, Insights and Forecast, 2021-2034

6.1. Market Analysis, Insights and Forecast - By Type
- 6.1.1. Diagnostics
  - 6.1.1.1. PET Radiopharmaceuticals
    - 6.1.1.1.1. FDG-PET/18F
    - 6.1.1.1.2. 68Ga
    - 6.1.1.1.3. 68Cu
    - 6.1.1.1.4. 11C
    - 6.1.1.1.5. Others
  - 6.1.1.2. SPECT Radiopharmaceuticals
    - 6.1.1.2.1. Technetium-99m
    - 6.1.1.2.2. Iodine-123
    - 6.1.1.2.3. Xenon-133
    - 6.1.1.2.4. Thallium-201
    - 6.1.1.2.5. Others
- 6.1.2. Therapeutics
  - 6.1.2.1. Ra-223
  - 6.1.2.2. Sm-153
  - 6.1.2.3. Lu-177
  - 6.1.2.4. I-131
  - 6.1.2.5. Y-90
  - 6.1.2.6. Others
6.2. Market Analysis, Insights and Forecast - By Application
- 6.2.1. Neurology
- 6.2.2. Cardiology
- 6.2.3. Oncology
- 6.2.4. Others
6.3. Market Analysis, Insights and Forecast - By End-user
- 6.3.1. Hospitals & Clinics
- 6.3.2. Diagnostic Centers
- 6.3.3. Others
6.4. Market Analysis, Insights and Forecast - By Country
- 6.4.1. U.S.
- 6.4.2. Canada

7. Europe Nuclear Medicine Market Analysis, Insights and Forecast, 2021-2034

7.1. Market Analysis, Insights and Forecast - By Type
- 7.1.1. Diagnostics
  - 7.1.1.1. PET Radiopharmaceuticals
    - 7.1.1.1.1. FDG-PET/18F
    - 7.1.1.1.2. 68Ga
    - 7.1.1.1.3. 68Cu
    - 7.1.1.1.4. 11C
    - 7.1.1.1.5. Others
  - 7.1.1.2. SPECT Radiopharmaceuticals
    - 7.1.1.2.1. Technetium-99m
    - 7.1.1.2.2. Iodine-123
    - 7.1.1.2.3. Xenon-133
    - 7.1.1.2.4. Thallium-201
    - 7.1.1.2.5. Others
- 7.1.2. Therapeutics
  - 7.1.2.1. Ra-223
  - 7.1.2.2. Sm-153
  - 7.1.2.3. Lu-177
  - 7.1.2.4. I-131
  - 7.1.2.5. Y-90
  - 7.1.2.6. Others
7.2. Market Analysis, Insights and Forecast - By Application
- 7.2.1. Neurology
- 7.2.2. Cardiology
- 7.2.3. Oncology
- 7.2.4. Others
7.3. Market Analysis, Insights and Forecast - By End-user
- 7.3.1. Hospitals & Clinics
- 7.3.2. Diagnostic Centers
- 7.3.3. Others
7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.4.1. U.K.
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Scandinavia
- 7.4.7. Rest of Europe

8. Asia Pacific Nuclear Medicine Market Analysis, Insights and Forecast, 2021-2034

8.1. Market Analysis, Insights and Forecast - By Type
- 8.1.1. Diagnostics
  - 8.1.1.1. PET Radiopharmaceuticals
    - 8.1.1.1.1. FDG-PET/18F
    - 8.1.1.1.2. 68Ga
    - 8.1.1.1.3. 68Cu
    - 8.1.1.1.4. 11C
    - 8.1.1.1.5. Others
  - 8.1.1.2. SPECT Radiopharmaceuticals
    - 8.1.1.2.1. Technetium-99m
    - 8.1.1.2.2. Iodine-123
    - 8.1.1.2.3. Xenon-133
    - 8.1.1.2.4. Thallium-201
    - 8.1.1.2.5. Others
- 8.1.2. Therapeutics
  - 8.1.2.1. Ra-223
  - 8.1.2.2. Sm-153
  - 8.1.2.3. Lu-177
  - 8.1.2.4. I-131
  - 8.1.2.5. Y-90
  - 8.1.2.6. Others
8.2. Market Analysis, Insights and Forecast - By Application
- 8.2.1. Neurology
- 8.2.2. Cardiology
- 8.2.3. Oncology
- 8.2.4. Others
8.3. Market Analysis, Insights and Forecast - By End-user
- 8.3.1. Hospitals & Clinics
- 8.3.2. Diagnostic Centers
- 8.3.3. Others
8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.4.1. China
- 8.4.2. Japan
- 8.4.3. India
- 8.4.4. Southeast Asia
- 8.4.5. Australia
- 8.4.6. Rest of Asia Pacific

9. Latin America Nuclear Medicine Market Analysis, Insights and Forecast, 2021-2034

9.1. Market Analysis, Insights and Forecast - By Type
- 9.1.1. Diagnostics
  - 9.1.1.1. PET Radiopharmaceuticals
    - 9.1.1.1.1. FDG-PET/18F
    - 9.1.1.1.2. 68Ga
    - 9.1.1.1.3. 68Cu
    - 9.1.1.1.4. 11C
    - 9.1.1.1.5. Others
  - 9.1.1.2. SPECT Radiopharmaceuticals
    - 9.1.1.2.1. Technetium-99m
    - 9.1.1.2.2. Iodine-123
    - 9.1.1.2.3. Xenon-133
    - 9.1.1.2.4. Thallium-201
    - 9.1.1.2.5. Others
- 9.1.2. Therapeutics
  - 9.1.2.1. Ra-223
  - 9.1.2.2. Sm-153
  - 9.1.2.3. Lu-177
  - 9.1.2.4. I-131
  - 9.1.2.5. Y-90
  - 9.1.2.6. Others
9.2. Market Analysis, Insights and Forecast - By Application
- 9.2.1. Neurology
- 9.2.2. Cardiology
- 9.2.3. Oncology
- 9.2.4. Others
9.3. Market Analysis, Insights and Forecast - By End-user
- 9.3.1. Hospitals & Clinics
- 9.3.2. Diagnostic Centers
- 9.3.3. Others
9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.4.1. Brazil
- 9.4.2. Mexico
- 9.4.3. Rest of Latin America

10. Middle East & Africa Nuclear Medicine Market Analysis, Insights and Forecast, 2021-2034

10.1. Market Analysis, Insights and Forecast - By Type
- 10.1.1. Diagnostics
  - 10.1.1.1. PET Radiopharmaceuticals
    - 10.1.1.1.1. FDG-PET/18F
    - 10.1.1.1.2. 68Ga
    - 10.1.1.1.3. 68Cu
    - 10.1.1.1.4. 11C
    - 10.1.1.1.5. Others
  - 10.1.1.2. SPECT Radiopharmaceuticals
    - 10.1.1.2.1. Technetium-99m
    - 10.1.1.2.2. Iodine-123
    - 10.1.1.2.3. Xenon-133
    - 10.1.1.2.4. Thallium-201
    - 10.1.1.2.5. Others
- 10.1.2. Therapeutics
  - 10.1.2.1. Ra-223
  - 10.1.2.2. Sm-153
  - 10.1.2.3. Lu-177
  - 10.1.2.4. I-131
  - 10.1.2.5. Y-90
  - 10.1.2.6. Others
10.2. Market Analysis, Insights and Forecast - By Application
- 10.2.1. Neurology
- 10.2.2. Cardiology
- 10.2.3. Oncology
- 10.2.4. Others
10.3. Market Analysis, Insights and Forecast - By End-user
- 10.3.1. Hospitals & Clinics
- 10.3.2. Diagnostic Centers
- 10.3.3. Others
10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.4.1. GCC
- 10.4.2. South Africa
- 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

11.1. Global Market Share Analysis (2025)
11.2. Company Profiles
- 11.2.1. GE HealthCare
- 11.2.2. Lantheus Holdings, Inc.
- 11.2.3. Nordion (Canada) Inc. (Sotera Health)
- 11.2.4. Bracco
- 11.2.5. Curium
- 11.2.6. Bayer AG
- 11.2.7. Siemens Healthineers AG
- 11.2.8. Novartis AG
- 11.2.9. Jubilant Pharmova Limited
- 11.2.10. Cardinal Health
- 11.2.11. Norgine
- 11.2.12. DuchemBio, Co., Ltd.

Product Code: FBI101812

List of Tables

Figure 1: Global Nuclear Medicine Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
Figure 2: Global Nuclear Medicine Market Value Share (%), by Type, 2025 & 2034
Figure 3: Global Nuclear Medicine Market Value Share (%), by Application, 2025 & 2034
Figure 4: Global Nuclear Medicine Market Value Share (%), by End-user, 2025 & 2034
Figure 5: Global Nuclear Medicine Market Value Share (%), by Region, 2025 & 2034
Figure 6: North America Nuclear Medicine Market Value (USD billion), by Type, 2025 & 2034
Figure 7: North America Nuclear Medicine Market Value Share (%), by Type, 2025
Figure 8: North America Nuclear Medicine Market Value (USD billion), by Application, 2025 & 2034
Figure 9: North America Nuclear Medicine Market Value Share (%), by Application, 2025
Figure 10: North America Nuclear Medicine Market Value (USD billion), by End-user, 2025 & 2034
Figure 11: North America Nuclear Medicine Market Value Share (%), by End-user, 2025
Figure 12: North America Nuclear Medicine Market Value (USD billion), by Country, 2025 & 2034
Figure 13: North America Nuclear Medicine Market Value Share (%), by Country, 2025
Figure 14: Europe Nuclear Medicine Market Value (USD billion), by Type, 2025 & 2034
Figure 15: Europe Nuclear Medicine Market Value Share (%), by Type, 2025
Figure 16: Europe Nuclear Medicine Market Value (USD billion), by Application, 2025 & 2034
Figure 17: Europe Nuclear Medicine Market Value Share (%), by Application, 2025
Figure 18: Europe Nuclear Medicine Market Value (USD billion), by End-user, 2025 & 2034
Figure 19: Europe Nuclear Medicine Market Value Share (%), by End-user, 2025
Figure 20: Europe Nuclear Medicine Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
Figure 21: Europe Nuclear Medicine Market Value Share (%), by Country/ Sub-region, 2025
Figure 22: Asia Pacific Nuclear Medicine Market Value (USD billion), by Type, 2025 & 2034
Figure 23: Asia Pacific Nuclear Medicine Market Value Share (%), by Type, 2025
Figure 24: Asia Pacific Nuclear Medicine Market Value (USD billion), by Application, 2025 & 2034
Figure 25: Asia Pacific Nuclear Medicine Market Value Share (%), by Application, 2025
Figure 26: Asia Pacific Nuclear Medicine Market Value (USD billion), by End-user, 2025 & 2034
Figure 27: Asia Pacific Nuclear Medicine Market Value Share (%), by End-user, 2025
Figure 28: Asia Pacific Nuclear Medicine Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
Figure 29: Asia Pacific Nuclear Medicine Market Value Share (%), by Country/ Sub-region, 2025
Figure 30: Latin America Nuclear Medicine Market Value (USD billion), by Type, 2025 & 2034
Figure 31: Latin America Nuclear Medicine Market Value Share (%), by Type, 2025
Figure 32: Latin America Nuclear Medicine Market Value (USD billion), by Application, 2025 & 2034
Figure 33: Latin America Nuclear Medicine Market Value Share (%), by Application, 2025
Figure 34: Latin America Nuclear Medicine Market Value (USD billion), by End-user, 2025 & 2034
Figure 35: Latin America Nuclear Medicine Market Value Share (%), by End-user, 2025
Figure 36: Latin America Nuclear Medicine Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
Figure 37: Latin America Nuclear Medicine Market Value Share (%), by Country/ Sub-region, 2025
Figure 38: Middle East & Africa Nuclear Medicine Market Value (USD billion), by Type, 2025 & 2034
Figure 39: Middle East & Africa Nuclear Medicine Market Value Share (%), by Type, 2025
Figure 40: Middle East & Africa Nuclear Medicine Market Value (USD billion), by Application, 2025 & 2034
Figure 41: Middle East & Africa Nuclear Medicine Market Value Share (%), by Application, 2025
Figure 42: Middle East & Africa Nuclear Medicine Market Value (USD billion), by End-user, 2025 & 2034
Figure 43: Middle East & Africa Nuclear Medicine Market Value Share (%), by End-user, 2025
Figure 44: Middle East & Africa Nuclear Medicine Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
Figure 45: Middle East & Africa Nuclear Medicine Market Value Share (%), by Country/ Sub-region, 2025
Figure 46: Global Nuclear Medicine Market Share (%), by Company, 2025

Nuclear Medicine Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034

Description

Table of Contents

List of Tables

Growth Factors of nuclear medicine Market

Regional Insights

Table of Content

1. Introduction

2. Executive Summary

3. Market Dynamics

4. Key Insights

5. Global Nuclear Medicine Market Analysis, Insights and Forecast, 2021-2034

6. North America Nuclear Medicine Market Analysis, Insights and Forecast, 2021-2034

7. Europe Nuclear Medicine Market Analysis, Insights and Forecast, 2021-2034

8. Asia Pacific Nuclear Medicine Market Analysis, Insights and Forecast, 2021-2034

9. Latin America Nuclear Medicine Market Analysis, Insights and Forecast, 2021-2034

10. Middle East & Africa Nuclear Medicine Market Analysis, Insights and Forecast, 2021-2034

11. Competitive Analysis

List of Tables